Skip to main content
. Author manuscript; available in PMC: 2020 Jul 22.
Published in final edited form as: J Med Chem. 2017 Jul 18;60(14):6273–6288. doi: 10.1021/acs.jmedchem.7b00584

Figure 4.

Figure 4.

Evaluation of compound (+)-19 in animal models of antipsychotic drug-like activity. (A) Locomotor activity reflecting baseline responses (0–15 min) and AMPH-induced hyperactivity with reductions by lorcaserin and (+)-19 (20–105 min). (B) Cumulative baseline locomotor activities (0–15 min), AMPH-induced hyperactivities, and reductions by lorcaserin and (+)-19 (20–105 min); ^ p < 0.05, compared to Sal-Sal group, baseline; * p < 0.05 compared to Sal-AMPH, Post-AMPH. (C) Locomotor activity reflecting baseline responses (0–15 min) and PCP-induced hyperactivity with effects by lorcaserin and (+)-19 (20–75 min). (B) Cumulative baseline locomotor activities (0–15 min), PCP-induced hyperactivities, and effects by lorcaserin and (+)-19 (20–75 min); ^ p < 0.05, compared to Sal-Sal group, baseline; * p < 0.05 compared to Sal-PCP, Post-PCP. N = 8–10 mice/group.